小细胞肺癌中的Delta-like配体3：潜在机制与治疗进展。
Delta-like ligand 3 in small cell lung cancer: potential mechanism and treatment progress.
发表日期：2023 Sep 14
作者：
Weichang Yang, Wenjun Wang, Zhouhua Li, Juan Wu, Xiaotian Huang, Jinbo Li, Xinyi Zhang, Xiaoqun Ye
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
小细胞肺癌（SCLC）是肺癌的一种病理类型，其特点是侵袭性强、恶性高和耐药性。SCLC的死亡率明显高于其他类型的肺癌，而SCLC患者的治疗选择有限。Delta样配体3（DLL3）是Notch信号通路的配体，它在调节SCLC细胞的增殖、发育和转移中起作用。许多研究表明，DLL3在SCLC细胞表面过度表达，提示DLL3是SCLC患者的潜在治疗靶点。目前正在进行一系列针对DLL3的药物试验。针对DLL3的药物Rova-T的III期临床试验未达到预期结果。然而，其他针对DLL3的药物，如AMG119、AMG757和DLL3靶向NIR-PIT，为SCLC治疗带来了新的想法。总体而言，DLL3仍然是SCLC的有价值的靶点。Copyright © 2023. Elsevier B.V.出版。
Small cell lung cancer (SCLC) is one of a pathological type of lung cancer, and it is characterized by invasiveness, high malignancy and refractoriness. The mortality rate of SCLC is significantly higher than other types of lung cancer, and the treatment options for SCLC patients are limited. Delta-like ligand 3 (DLL3) is a Notch signaling ligand that plays a role in regulating the proliferation, development and metastasis of SCLC cells. Mnay studies have shown that DLL3 is overexpressed on the surface of SCLC cells, suggesting that DLL3 is a potential target for SCLC patients. A series of drug trials targeting DLL3 are underway. The Phase III clinical trials of Rova-T, a drug targeting DLL3, have not yielded the expected results. However, other drugs that target DLL3, such as AMG119, AMG757 and DLL3-targeted NIR-PIT, bring new ideas for SCLC treatment. Overall, DLL3 remains a valuable target for SCLC.Copyright © 2023. Published by Elsevier B.V.